A therapeutic dendritic cell-based vaccine for HIV-1 infection.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 21233310.
- Also identified by DOI 10.1093/infdis/jiq077 and PMC identifier 3071229.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A double-blinded, controlled study of vaccination of untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection with 3 doses of autologous monocyte-derived dendritic cells (MD-DCs) pulsed with heat inactivated autologous HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first vaccination (primary end point), a modest significant decrease in plasma viral load was observed in vaccine recipients, compared with control subjects (P = .03). In addition, the change in plasma viral load after vaccination tended to be inversely associated with the increase in HIV-specific T cell responses in vaccinated patients but tended to be directly correlated with HIV-specific T cell responses in control subjects.
Medical subject headings
- AIDS Vaccines
- Dendritic Cells
- HIV Infections
- HIV-1
- Immunotherapy